Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Breast Neoplasms 1

Interventions

Oxaliplatin 271 Fluorouracil 268 Capecitabine 234 Leucovorin 209 Irinotecan 152 Radiotherapy 138 Bevacizumab 114 Cetuximab 82 Surgical Procedures, Operative 51 Folfox protocol 48 Neoadjuvant Therapy 45 Drug Therapy 43 Radiation 42 Chemotherapy, Adjuvant 34 Chemoradiotherapy 34 Panitumumab 27 Magnetic Resonance Spectroscopy 26 XELOX 25 Radiotherapy, Intensity-Modulated 23 Biopsy 20 Surveys and Questionnaires 18 Laparoscopy 18 Proctectomy 17 Floxuridine 17 Early Intervention, Educational 16 Nivolumab 15 Immunohistochemistry 15 Gene Expression Profiling 15 Gemcitabine 15 pembrolizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × Hydralazine × Clear all

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡